GSK's MenABCWY vaccine set to revolutionize meningococcal disease prevention market
Should the MenABCWY vaccine perform well in upcoming Phase III studies, it has the potential to become market leader, says GlobalData.
A vaccine protecting against meningococcal serogroups A, B, C, W, and Y (MenABCWY) is set to revolutionize meningococcal disease prevention across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and Brazil, according to research and consulting firm GlobalData.
The company’s report — PharmaPoint: Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2025 — states that of the three major meningococcal vaccines currently being developed in the 8MM, only GlaxoSmithKline’s (GSK) MenABCWY vaccine has the potential to significantly change the approach used by countries to prevent meningococcal disease. Its launch would offer a vaccine that can protect against all common serogroups found in the 8MM in a single product and, should it perform well in upcoming Phase III studies, has the potential to become the leader in a market projected to be worth $1.8 billion by 2025.
Mirco Junker, GlobalData’s Analyst covering Infectious Diseases, explains: “MenABCWY, effectively a co-formulation of GSK’s Menveo and Bexsero, could reduce the shot burden for patients, and will hold an advantage over other formulations in its combination of conjugated polysaccharides and purified protein-based antigens.
“While polysaccharide vaccines can provide excellent protection in individuals against a specific set of serogroups, these vaccines are limited in their protective ability to these serogroups. By contrast, protein-based meningococcal vaccines, which include the MenB vaccine, can also protect against strains from other serogroups.
“Combining polysaccharides from a MenACWY vaccine with the protein-based antigens from Bexsero into one vaccine, therefore, might provide effective protective coverage.”
Following the expected launch of a MenABCWY vaccine in the US and the five European markets in 2020, national routine immunization schedules are likely to be altered, with the new MenABCWY vaccine potentially replacing a majority of routinely administered meningococcal vaccines. Indeed, MenABCWY is touted as a possible replacement for the MenACWY booster currently recommended to be administered to adolescents in the US.
Junker concludes: “Currently, there are no products in the pipeline specifically designed to provide long-term protection against invasive meningococcal disease. However, several clinical trials, including for MenABCWY, are being conducted to further address this important unmet need in meningococcal disease prevention.”
GlobalData forecasts that GSK’s MenABCWY vaccine will have sales of just under $437 million in 2025 across the 8MM.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance